Johnson & Johnson has delivered a strong 28% total return year-to-date in 2026, outperforming major benchmarks like the S&P 500 ETF and healthcare sector ETF XLV. Despite solid second-quarter results and an upgraded full-year 2026 guidance driven by pharmaceutical momentum, the stock now trades at a premium valuation. Key risks include potential softness in MedTech growth, ongoing litigation challenges, and broader macroeconomic uncertainties. Technically, the stock remains in an uptrend but shows signs of possible near-term consolidation due to negative RSI divergence and high valuation, leading analysts to maintain a hold rating rather than recommending a buy or sell.
Johnson & Johnson's recent quarterly report showed its MedTech segment sales fell short of Wall Street expectations, primarily due to pricing pressures in China and budget cuts in Europe. This shortfall caused the company's shares to decline, impacti...
Johnson & Johnson reported strong Q3 earnings with a 6% sales increase and raised its full-year guidance, yet its stock dropped nearly 6% after a weak MedTech segment performance and costs from recent acquisitions. Despite the selloff, key drug sales...
Johnson & Johnson reported resilient sales growth and exceeded earnings expectations, driven by promising results in its Innovative Medicine segment and potential growth from its MedTech OTTAVA system. However, softness in profitability and ongoing r...
Johnson & Johnson reported a 6% revenue increase to $25.4 billion in Q3 2026, but earnings per share (EPS) declined 7.5% year-on-year, causing the stock to fall 5%. The company set aside $5.5 billion to resolve talc litigation, aiming for 95% plainti...
Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which off...
